Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

Irene Ganan-Gomez, Hui Yang, Feiyang Ma, Guillermo Montalban-Bravo, Natthakan Thongon, Valentina Marchica, Guillaume Richard-Carpentier, Kelly Chien, Ganiraju Manyam, Feng Wang, Ana Alfonso, Shuaitong Chen, Caleb Class, Rashmi Kanagal-Shamanna, Justin P. Ingram, Yamini Ogoti, Ashley Rose, Sanam Loghavi, Pamela Lockyer, Benedetta CamboMuharrem Muftuoglu, Sarah Schneider, Vera Adema, Michael McLellan, John Garza, Matteo Marchesini, Nicola Giuliani, Matteo Pellegrini, Jing Wang, Jason Walker, Ziyi Li, Koichi Takahashi, Joel D. Leverson, Carlos Bueso-Ramos, Michael Andreeff, Karen Clise-Dwyer, Guillermo Garcia-Manero, Simona Colla

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

In the version of this article initially published, the name of the Edward P. Evans Foundation was shown incorrectly in the first sentence of the Acknowledgements. The name has been corrected in the HTML and PDF versions of the paper.

Original languageEnglish (US)
Pages (from-to)1097
Number of pages1
JournalNature medicine
Volume28
Issue number5
DOIs
StatePublished - May 2022

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

MD Anderson CCSG core facilities

  • Biostatistics Resource Group
  • Bioinformatics Shared Resource

Fingerprint

Dive into the research topics of 'Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)'. Together they form a unique fingerprint.

Cite this